Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant

Raleigh A. Bowden, Sherrill J. Slichter, Merlin H. Sayers, Motomi Mori, Monica J. Cays, Joel D. Meyers

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Seventy-seven cytomegalovirus (CMV)-seronegative marrow transplant patients were randomized in a prospective controlled trial comparing the use of leukocyte-depleted platelets plus CMV-seronegative red blood cells with standard unscreened blood products for the prevention of primary CMV infection during the first 100 days after transplant. Eligible patients included CMV-seronegative patients undergoing autologous transplant or seronegative patients undergoing allogeneic transplant for aplastic anemia or non-hematologic malignancy who had seronegative marrow donors. Patients and marrow donors were serologically screened for CMV and randomized before conditioning for transplant and followed for CMV infection with weekly cultures of throat, urine, and blood and with weekly CMV serologies until day 100 after transplant. Leukocyte-depleted platelets were prepared by centrifugation, a procedure that removed greater than 99% of leukocytes. There were no CMV infections observed in 35 evaluable treatment patients compared with seven infections in 30 evaluable control patients (P = .0013). There was no statistically significant difference in the mean number of platelet concentrates in the treatment patients (164 concentrates) compared with the control patients (126 concentrates). Leukocyte-depleted platelets plus CMV-seronegative red blood cells are highly effective in preventing primary CMV infection after marrow transplant.

Original languageEnglish (US)
Pages (from-to)246-250
Number of pages5
JournalBlood
Volume78
Issue number1
StatePublished - Jul 1 1991

Fingerprint

Transplants
Cytomegalovirus Infections
Primary Prevention
Platelets
Cytomegalovirus
Leukocytes
Blood
Blood Platelets
Erythrocytes
Bone Marrow
Cells
Patient treatment
Centrifugation
Autografts
Tissue Donors
Aplastic Anemia
Serology
Pharynx
Platelet Count
Urine

ASJC Scopus subject areas

  • Hematology

Cite this

Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. / Bowden, Raleigh A.; Slichter, Sherrill J.; Sayers, Merlin H.; Mori, Motomi; Cays, Monica J.; Meyers, Joel D.

In: Blood, Vol. 78, No. 1, 01.07.1991, p. 246-250.

Research output: Contribution to journalArticle

Bowden, Raleigh A. ; Slichter, Sherrill J. ; Sayers, Merlin H. ; Mori, Motomi ; Cays, Monica J. ; Meyers, Joel D. / Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. In: Blood. 1991 ; Vol. 78, No. 1. pp. 246-250.
@article{f5fecedf785b4b578fa1f635e62dadab,
title = "Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant",
abstract = "Seventy-seven cytomegalovirus (CMV)-seronegative marrow transplant patients were randomized in a prospective controlled trial comparing the use of leukocyte-depleted platelets plus CMV-seronegative red blood cells with standard unscreened blood products for the prevention of primary CMV infection during the first 100 days after transplant. Eligible patients included CMV-seronegative patients undergoing autologous transplant or seronegative patients undergoing allogeneic transplant for aplastic anemia or non-hematologic malignancy who had seronegative marrow donors. Patients and marrow donors were serologically screened for CMV and randomized before conditioning for transplant and followed for CMV infection with weekly cultures of throat, urine, and blood and with weekly CMV serologies until day 100 after transplant. Leukocyte-depleted platelets were prepared by centrifugation, a procedure that removed greater than 99{\%} of leukocytes. There were no CMV infections observed in 35 evaluable treatment patients compared with seven infections in 30 evaluable control patients (P = .0013). There was no statistically significant difference in the mean number of platelet concentrates in the treatment patients (164 concentrates) compared with the control patients (126 concentrates). Leukocyte-depleted platelets plus CMV-seronegative red blood cells are highly effective in preventing primary CMV infection after marrow transplant.",
author = "Bowden, {Raleigh A.} and Slichter, {Sherrill J.} and Sayers, {Merlin H.} and Motomi Mori and Cays, {Monica J.} and Meyers, {Joel D.}",
year = "1991",
month = "7",
day = "1",
language = "English (US)",
volume = "78",
pages = "246--250",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant

AU - Bowden, Raleigh A.

AU - Slichter, Sherrill J.

AU - Sayers, Merlin H.

AU - Mori, Motomi

AU - Cays, Monica J.

AU - Meyers, Joel D.

PY - 1991/7/1

Y1 - 1991/7/1

N2 - Seventy-seven cytomegalovirus (CMV)-seronegative marrow transplant patients were randomized in a prospective controlled trial comparing the use of leukocyte-depleted platelets plus CMV-seronegative red blood cells with standard unscreened blood products for the prevention of primary CMV infection during the first 100 days after transplant. Eligible patients included CMV-seronegative patients undergoing autologous transplant or seronegative patients undergoing allogeneic transplant for aplastic anemia or non-hematologic malignancy who had seronegative marrow donors. Patients and marrow donors were serologically screened for CMV and randomized before conditioning for transplant and followed for CMV infection with weekly cultures of throat, urine, and blood and with weekly CMV serologies until day 100 after transplant. Leukocyte-depleted platelets were prepared by centrifugation, a procedure that removed greater than 99% of leukocytes. There were no CMV infections observed in 35 evaluable treatment patients compared with seven infections in 30 evaluable control patients (P = .0013). There was no statistically significant difference in the mean number of platelet concentrates in the treatment patients (164 concentrates) compared with the control patients (126 concentrates). Leukocyte-depleted platelets plus CMV-seronegative red blood cells are highly effective in preventing primary CMV infection after marrow transplant.

AB - Seventy-seven cytomegalovirus (CMV)-seronegative marrow transplant patients were randomized in a prospective controlled trial comparing the use of leukocyte-depleted platelets plus CMV-seronegative red blood cells with standard unscreened blood products for the prevention of primary CMV infection during the first 100 days after transplant. Eligible patients included CMV-seronegative patients undergoing autologous transplant or seronegative patients undergoing allogeneic transplant for aplastic anemia or non-hematologic malignancy who had seronegative marrow donors. Patients and marrow donors were serologically screened for CMV and randomized before conditioning for transplant and followed for CMV infection with weekly cultures of throat, urine, and blood and with weekly CMV serologies until day 100 after transplant. Leukocyte-depleted platelets were prepared by centrifugation, a procedure that removed greater than 99% of leukocytes. There were no CMV infections observed in 35 evaluable treatment patients compared with seven infections in 30 evaluable control patients (P = .0013). There was no statistically significant difference in the mean number of platelet concentrates in the treatment patients (164 concentrates) compared with the control patients (126 concentrates). Leukocyte-depleted platelets plus CMV-seronegative red blood cells are highly effective in preventing primary CMV infection after marrow transplant.

UR - http://www.scopus.com/inward/record.url?scp=0025851442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025851442&partnerID=8YFLogxK

M3 - Article

VL - 78

SP - 246

EP - 250

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -